272 related articles for article (PubMed ID: 8683243)
1. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
2. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
3. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
4. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
5. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
6. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Pawlicki M; Rolski J; WiczyĆska B; Rychlik U
Ginekol Pol; 1998 Jul; 69(7):580-5. PubMed ID: 9810418
[TBL] [Abstract][Full Text] [Related]
8. [Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].
Heidenreich A; Marx FJ; Peters HJ
Urologe A; 1999 Nov; 38(6):586-91. PubMed ID: 10591805
[TBL] [Abstract][Full Text] [Related]
9. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
11. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
13. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
14. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
[TBL] [Abstract][Full Text] [Related]
15. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
17. Advances in supportive therapy.
Facchini T
Zentralbl Gynakol; 1996; 118(10):589-90. PubMed ID: 8912478
[No Abstract] [Full Text] [Related]
18. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Kusenda Z; Kerger J; Awada A; Geurs F; Van Vreckem A; Habboubi N; Piccart MJ
Support Care Cancer; 1997 Sep; 5(5):414-6. PubMed ID: 9322355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]